Clinical trial
Vaccine Therapy in Treating Women With Metastatic Breast Cancer
NCT00003638 · Oncothyreon Canada Inc., Industry · Completed
Key facts
| NCT number | NCT00003638 |
|---|---|
| Title | Vaccine Therapy in Treating Women With Metastatic Breast Cancer |
| Official title | A Multi-Center Phase III Randomized, Controlled Study of Theratope Vaccine for Metastatic Breast Cancer |
| Lead sponsor | Oncothyreon Canada Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug |
| Interventions | Detox-B adjuvant, THERATOPE STn-KLH vaccine, keyhole limpet hemocyanin, cyclophosphamide |
| Enrollment | 950 |
| Start date | Jan 1, 1999 |
| Primary completion | Jan 1, 2007 |
| Completion | Dec 1, 2008 |
| First posted | May 3, 2004 |
| Last update posted | Mar 26, 2013 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: